



## AtriCure to Participate at the SVB Leerink 9th Annual Global Healthcare Conference

February 3, 2020

MASON, Ohio--(BUSINESS WIRE)--Feb. 3, 2020-- [AtriCure, Inc. \(Nasdaq: ATRC\)](#), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 9<sup>th</sup> Annual Global Healthcare Conference in New York City.

AtriCure's management is scheduled to present on Tuesday, February 25, 2020, at 11:30 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at <https://ir.atricure.com>.

### About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator<sup>®</sup> Synergy<sup>™</sup> Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip<sup>®</sup> Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit [AtriCure.com](http://AtriCure.com) or follow us on Twitter [@AtriCure](https://twitter.com/AtriCure).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200203005046/en/>

Source: AtriCure, Inc.

Andy Wade  
AtriCure, Inc.  
Senior Vice President and Chief Financial Officer  
(513) 755-4564  
[awade@atricure.com](mailto:awade@atricure.com)

Lynn Pieper Lewis  
Gilmartin Group  
Investor Relations  
(415) 937-5402  
[lynn@gilmartinir.com](mailto:lynn@gilmartinir.com)